Moderna shares have increased in value after it was disclosed that the company had been working on a hantavirus vaccine before the current outbreak. The revelation of this pre-outbreak work has had a positive impact on the company's shares. The existence of this prior vaccine work has been made public, although details of the work are not specified in the available information.